CEL-SCI Corporation (NYSE American: CVM) today announced it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the clinical hold that had been imposed on the Company’s Phase 3 cancer study with Multikine* (Leukocyte Interleukin, Inj.) has been removed and that all clinical trial activities under this Investigational New Drug application (IND) may resume.
To post job/internship opportunities, please email BHI@BioHealthInnovation.org your request with the link/URL to your specific opportunity or to your page highlighting multiple opportunities. Please also notify us once these position(s) are filled. Thank you.
3i Diagnostics, Inc. – Gaithersburg
Advanced BioScience Laboratories, Inc. (ABL) – Rockville
Aledade – Bethesda
Altimmune – Gaithersburg
Amarex Clinical Research – Germantown
American Gene Technologies – Rockville
Aphena – Easton
ARPA-H – Bethesda
AstraZeneca – Frederick, Gaithersburg
ATCC – Gaithersburg, MD and Manassas, VA
Aurinia Pharmaceuticals – Rockville
Autolus – Gaithersburg, Rockville
b well – Baltimore
BioFactura – Frederick
Cartesian Therapeutics – Gaithersburg
Catalent – Harmans
Champions Oncology, Inc. – Rockville
Children’s National – DC
DrFirst – Rockville
Early Charm – Baltimore
Elixirgen Scientific – Baltimore
Ellume – Frederick
Emergent BioSolutions, Inc. – Baltimore, Gaithersburg, Rockville
EMMES Corp – Frederick, Rockville
Emocha Mobile Health, Inc. – Baltimore
Frederick National Lab for Cancer Research – Frederick
GetWellNetwork, Inc. – Bethesda
GSK Global Vaccines US R&D Center – Rockville
GlycoMimetics, Inc. – Rockville
Henry Jackson Foundation – Bethesda and Silver Spring, MD
Horizon Therapeutics – Gaithersburg
Immunomic Therapeutics – Rockville
Institute for In Vitro Sciences – Gaithersburg
Intralytix – Baltimore and Columbia
Jecho Laboratories – Frederick
Johns Hopkins Technology Ventures – Baltimore
Johnson & Johnson – DC and Gaithersburg
KeyGene USA – Rockville
Kite Pharma (a Gilead Company) – Frederick, Gaithersburg
Landos Biopharma, Inc. – Reston
Leadiant Biosciences – Gaithersburg
Leidos Biomedical Research – Frederick
Lieber Institute for Brain Development – Baltimore
Lonza – Walkersville
Lupin Pharmaceuticals, Inc. – Baltimore
MacroGenics – Rockville
Maryland Department of Commerce – Baltimore
MaxCyte, Inc. – Gaithersburg
Maxim Biomedical – Rockville
Meso Scale Diagnostics – Rockville, Gaithersburg
Miltenyi Biotec – Gaithersburg
Mimetas – Gaithersburg
National Institutes of Health (NIH) – Bethesda
Netrias– Bethesda and Arlington
NexImmune – Gaithersburg
Nobile Life Sciences – Baltimore
Novavax, Inc. – Gaithersburg, Rockville
Novel MicroDevices – Baltimore
Noxilizer – Baltimore
Precigen – Germantown
Protenus – Baltimore
QIAGEN Sciences – Germantown, Frederick
Quality Biological – Gaithersburg, MD and D.C.
REGENXBIO Inc. – Rockville
RoosterBio, Inc. – Frederick
Root3Labs – Randallstown
Sanaria, Inc. – Rockville
SeraCare – Gaithersburg
Senseonics – Germantown
Sirnaomics – Gaithersburg
Smith & Nephew – Columbia, MD
SoBran – Bethesda, Baltimore, Poolesville, Silver Spring
Sonavex Surgical, Inc. – Baltimore
Sterilex – Hunt Valley
Supernus Pharmaceuticals – Rockville
ThermoFisher Scientific – Baltimore, Bethesda, Frederick, DC
United Therapeutics – Silver Spring
University of Maryland Medical System – Maryland
U.S. Food and Drug Administration (FDA)
US Pharmacopeia – Rockville
Vaccitech – Maryland
Vanda Pharma – D.C.
Vheda Health – Columbia
WellDoc – Columbia
Westat – Rockville
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced the publication of results from a Phase 1/2a study of intrathecal administration of VTS-270, a 2-hydoxypropyl-β-cyclodextrin (HPβCD) under investigation for treatment of Niemann-Pick Disease Type C1 (NPC-1). The results of the study were published in the August 10, 2017 issue of The Lancet and can be found at http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)31465-4.pdf.
25-year biopharma industry veteran joins the Company to drive further growth of its innovative high-performance cell engineering platform for use in commercial drug development
MaxCyte, a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, announced today that it has appointed Brad Calvin, a 25-year veteran within the drug development and biotechnology industries, as Executive Vice President of Global Marketing. In his role, Mr. Calvin is responsible for leading MaxCyte’s marketing function to drive growth of the Company’s drug discovery and cell therapy business.
Doug Doerfler, Chief Executive Officer, said, “We are delighted to have someone of Brad’s caliber join MaxCyte to lead our marketing and market development efforts. Brad’s broad biopharmaceutical industry experience has provided him with an in-depth understanding of working across global markets and supporting all phases of product life cycles. His appointment comes at an opportune time for the Company, as we continue to develop new offerings based on our Flow Electroporation® Technology.”
From companies created to work in best in today’s new value-based healthcare system to precision medicine, data analytics and interoperability, you can count on a healthcare IT landscape that is always in flux, thanks to new approaches driven by entrepreneurs who are adept at shaking things up.
This gallery highlights some of the most promising new companies and the founders and CEOs who are making news in 2017. Healthcare IT News is keeping tabs on the most exciting and promising new ventures.
U.S. Sen. Benjamin L. Cardin, JD ‘67, returned to his alma mater, the University of Maryland, Baltimore (UMB), to tour the UM BioPark and host a roundtable discussion with university leaders and biomedical innovators, highlighting such topics as bipartisan solutions to health care policy and ways to encourage small business innovation.
“I always get excited being here,” said Cardin as he kicked off the discussion Aug. 10. “It does energize me. After what I’ve just gone through this month in the United States Senate, it’s good to be here, to realize there is real life going on in our communities.”
You don’t have to go to Johns Hopkins University to make a lot of money. In fact, you can make more money by going elsewhere in Maryland. The U.S. Department of Education offers a College Scorecard that provides would-be attendees many of the resources they need in deciding where to apply and, ultimately, where to attend.
The Trump administration is pushing for dramatic cutbacks at the National Institutes of Health. The proposed $5.8 billion cut from the agency’s annual $32 billion budget would translate into 5,000 to 8,000 fewer grants per year for basic medical research.
But the impact of such cuts would actually be much broader, totaling $15 billion in lost economic activity and 90,000 jobs lost nationwide.
Women Building Bio: the XX factor is a day long conference to recognize and learn from leading women in the bioscience industry as pioneers paving the path to success. These women have faced their own unique challenges and carved out lasting legacies.
This day will catalyze the formation of a diverse network. It is a convergence of academia and industry, men and women, researchers and innovators, professionals and decision-makers gathering together to build relationships. This day long conference provides extraordinary opportunities to exchange new ideas, highlight areas of bioscience and research opportunities, and find partners for future collaboration.
In a striking advance that helps open the door to organ transplants from animals, researchers have created gene-edited piglets cleansed of viruses that might cause disease in humans.
